ew result better expect guidanc
adjust impact
summari close ew report revenu
underli adj ep
ahead consensu ahead
valv replac sale underli
consensu expect
adjust estim impact ew revis
total revenu guidanc vs prior
midpoint ew also lower ep guidanc
vs previous
across busi last week march due
look ahead ew expect impact sever
disrupt gradual recoveri
reach normal growth rate line
expect overal ew believ structur heart patient
delay treatment eventu get treat receiv
procedur though uncertainti time
chang estim rais revenu estim
underli rais adj ep
estim report rais
revenu estim underli
rais adj ep estim report
rais price target base
adj ep
continu follow page
compani data secur llc estim reuter
compani data secur llc estim reuter
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
tavr sale exceed expect impact go forward sever ww tavr
transcathet aortic valv replac sale consensu
estim previous updat impact underli tavr growth
quarter exceed estim compar accord
ew tavr procedur growth in-lin growth rate earli march ew tavr
perform compris growth us mid-teen growth ou ew encount much
impact japan expect meaning roll-out sapien
ultra manag note continu advanc exit quarter case
us eu current ew paus proctor center yet train new ultra
devic plan resum roll-out condit stabl separ ew note
remain stabl world-wide look ahead ew expect impact
disrupt gradual recoveri reach normal growth rate line
sale expect ew provid guidanc expect full year tavr sale
growth flat rang vs prior growth market standpoint
ew remain consist estim market low-doubl digit compound-annual-growth-rate
tmtt line expect clinic trial enrol paus expect contribut
transcathet mitral/tricuspid therapi tmtt rel modest in-lin
expect accord manag tmtt track line expect earli
march declin sharpli quarter ew saw strong adopt pascal europ
clinic studi ew paus enrol mitral tricuspid trial manag note
could probabl take around two quarter resum on-going studi ew aim provid
updat pascal clasp studi earli experi evoqu trial cardioband upcom
europcr meet may ew anticip signific declin transcathet mitral tricuspid
procedur compani expect recoveri begin overal expect
sale vs prior ew manag remain optimist ww tmtt market
opportun
surgic structur heart expect ew report surgic structur heart ssh sale
underli came ahead consensus/our estim
respect declin result continu lower surgic aortic valv replac savr
procedur due expans tavr us relat disrupt last week
march ew inspiri valv continu drive increment share savr procedur lead
savr valv us japan per manag separ ew note aim launch harpoon
europ relat disrupt subsid ssh growth guidanc declin
prior growth expect growth turn posit
critic sale expect ew report critic cc sale
underli estim consensu result led strong
demand truwav dispos pressur monitor devic europ off-set lower order
enhanc surgic recoveri portfolio ew note cc focus help two distinct group patient
larger group need hemodynam monitor surgic set smaller group need
support icu pandem remain activ revenu surgic recoveri
product significantli lower partial off-set increas demand icu product compani
also see delay hemospher order us hospit limit capit spend
focu ew expect cc sale flat rang
guidanc adjust impact call ew adjust guidanc
impact similar medic devic compani ew expect sever hit
pandem measur recoveri follow sale reach level prior
expect pre impact compani guidanc anticip second wave
infect ew expect sale prior adjust ep
prior regard currenc ew anticip fx headwind roughli
top line vs headwind roughli expect previous
comment item manag expect gross margin declin later year
sell higher cost inventori ew expect expens come given paus enrol tmtt
clinic trial tax rate guidanc widen prior due uncertainti
addit expect averag share count prior lastli
manag updat free cash flow guidanc believ would like fall short
guidanc laid previous ew expect gener sale
compar prior consensu
price target
price target assum ep estim risk includ
greater share loss model delay mitral program neg clinic data
believ upcom data pipelin product help ew address new competit
transcathet mitral valv opportun signific catalyst
irvin california -base edward lifesci ew develop manufactur market product
design heart valv diseas cardiac surgeri critic care edward revenu reach
billion come transcathet heart valv therapi thv busi ew
player transcathet heart valv therapi market
